A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
Phase of Trial: Phase III
Latest Information Update: 03 May 2017
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- Acronyms YingLong
- Sponsors AstraZeneca
- 28 Apr 2017 Status changed from active, no longer recruiting to completed.
- 03 Jan 2017 Planned End Date changed from 1 Jul 2017 to 1 Apr 2017.
- 03 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Apr 2017.